罗氟司特联合长效β2受体激动剂/长效抗胆碱能药物/吸入性糖皮质激素治疗慢性阻塞性肺疾病患者的效果。 - Suppr

The effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients.

作者信息

De Backer Wilfried, Vos Wim, Van Holsbeke Cedric, Vinchurkar Samir, Claes Rita, Hufkens Annemie, Parizel Paul M, Bedert Lieven, De Backer Jan

机构信息

Dept of Respiratory Medicine, University Hospital Antwerp, Antwerp, Belgium.

Fluidda nv, Kontich, Belgium.

出版信息

Eur Respir J. 2014 Aug;44(2):527-9. doi: 10.1183/09031936.00011714. Epub 2014 May 2.

DOI:10.1183/09031936.00011714

PMID:24791831

Abstract

摘要

相似文献

The effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients.

Eur Respir J. 2014 Aug;44(2):527-9. doi: 10.1183/09031936.00011714. Epub 2014 May 2.

Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.

Int J Chron Obstruct Pulmon Dis. 2012;7:183-99. doi: 10.2147/COPD.S29820. Epub 2012 Mar 19.

Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland.

Int J Chron Obstruct Pulmon Dis. 2013;8:79-87. doi: 10.2147/COPD.S37486. Epub 2013 Jan 30.

[Phosphodiesterase-4 inhibitors: roflumilast].

Rev Clin Esp. 2011 Mar;211 Suppl 2:22-30. doi: 10.1016/S0014-2565(11)70008-X.

[COPD and diabetes mellitus. Does pulmonary medication modify blood glucose metabolism?].

MMW Fortschr Med. 2011 Mar 17;153(11):17.

Roflumilast for the treatment of chronic obstructive pulmonary disease.

Expert Rev Respir Med. 2010 Oct;4(5):543-55. doi: 10.1586/ers.10.56.

How phosphodiesterase 4 inhibitors work in patients with chronic obstructive pulmonary disease of the severe, bronchitic, frequent exacerbator phenotype.

Clin Chest Med. 2014 Mar;35(1):203-17. doi: 10.1016/j.ccm.2013.09.007. Epub 2013 Dec 12.

[Roflumilast in combination with long-acting bronchodilators in the management of patients with severe and very severe COPD. A cost-effectiveness analysis for Germany].

Dtsch Med Wochenschr. 2013 Jan;138(4):119-25. doi: 10.1055/s-0032-1327416. Epub 2013 Jan 15.

Roflumilast for asthma: Weighing the evidence.

Pulm Pharmacol Ther. 2015 Dec;35 Suppl:S1-3. doi: 10.1016/j.pupt.2015.08.001. Epub 2015 Aug 13.

Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients.

Int J Chron Obstruct Pulmon Dis. 2015 Jun 15;10:1123-8. doi: 10.2147/COPD.S83205. eCollection 2015.

引用本文的文献

Chronic Obstructive Pulmonary Disease (COPD): Developments in Pharmacological Treatments.

Drugs. 2025 May 20. doi: 10.1007/s40265-025-02188-8.

Differential response to roflumilast in patients with chronic obstructive pulmonary disease: real-world evidence.

J Thorac Dis. 2024 Feb 29;16(2):1338-1349. doi: 10.21037/jtd-23-1129. Epub 2024 Feb 27.

The effects of benralizumab on airway geometry and dynamics in severe eosinophilic asthma: a single-arm study design exploring a functional respiratory imaging approach.

Respir Res. 2023 May 3;24(1):121. doi: 10.1186/s12931-023-02415-4.

Effects of Roflumilast on Patients with Chronic Obstructive Pulmonary Disease Treated with Inhaled Corticosteroid/Long-Acting 2 Agonist: A Meta-analysis.

Comput Math Methods Med. 2022 Jul 23;2022:8101099. doi: 10.1155/2022/8101099. eCollection 2022.

Phosphodiesterase-4 Inhibitors for Non-COPD Respiratory Diseases.

Front Pharmacol. 2021 Aug 5;12:518345. doi: 10.3389/fphar.2021.518345. eCollection 2021.

Innovating on Inhaled Bioequivalence: A Critical Analysis of the Current Limitations, Potential Solutions and Stakeholders of the Process.

Pharmaceutics. 2021 Jul 9;13(7):1051. doi: 10.3390/pharmaceutics13071051.

A Functional Respiratory Imaging Approach to the Effect of an Oscillating Positive Expiratory Pressure Device in Chronic Obstructive Pulmonary Disease.

Int J Chron Obstruct Pulmon Dis. 2020 Jun 4;15:1261-1268. doi: 10.2147/COPD.S242191. eCollection 2020.

Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease.

Cochrane Database Syst Rev. 2020 May 1;5(5):CD002309. doi: 10.1002/14651858.CD002309.pub6.

Interventions for promoting physical activity in people with chronic obstructive pulmonary disease (COPD).

Cochrane Database Syst Rev. 2020 Apr 16;4(4):CD012626. doi: 10.1002/14651858.CD012626.pub2.

Effects of Roflumilast on Rehospitalization and Mortality in Patients.

Chronic Obstr Pulm Dis. 2018 Dec 20;6(1):74-85. doi: 10.15326/jcopdf.6.1.2018.0139.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

The effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients.

作者信息

De Backer Wilfried, Vos Wim, Van Holsbeke Cedric, Vinchurkar Samir, Claes Rita, Hufkens Annemie, Parizel Paul M, Bedert Lieven, De Backer Jan

机构信息

Dept of Respiratory Medicine, University Hospital Antwerp, Antwerp, Belgium.

Fluidda nv, Kontich, Belgium.

出版信息

Eur Respir J. 2014 Aug;44(2):527-9. doi: 10.1183/09031936.00011714. Epub 2014 May 2.

DOI:10.1183/09031936.00011714

PMID:24791831

Abstract

摘要

相似文献

The effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients.

Eur Respir J. 2014 Aug;44(2):527-9. doi: 10.1183/09031936.00011714. Epub 2014 May 2.

Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.

Int J Chron Obstruct Pulmon Dis. 2012;7:183-99. doi: 10.2147/COPD.S29820. Epub 2012 Mar 19.

Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland.

Int J Chron Obstruct Pulmon Dis. 2013;8:79-87. doi: 10.2147/COPD.S37486. Epub 2013 Jan 30.

[Phosphodiesterase-4 inhibitors: roflumilast].

Rev Clin Esp. 2011 Mar;211 Suppl 2:22-30. doi: 10.1016/S0014-2565(11)70008-X.

[COPD and diabetes mellitus. Does pulmonary medication modify blood glucose metabolism?].

MMW Fortschr Med. 2011 Mar 17;153(11):17.

Roflumilast for the treatment of chronic obstructive pulmonary disease.

Expert Rev Respir Med. 2010 Oct;4(5):543-55. doi: 10.1586/ers.10.56.

How phosphodiesterase 4 inhibitors work in patients with chronic obstructive pulmonary disease of the severe, bronchitic, frequent exacerbator phenotype.

Clin Chest Med. 2014 Mar;35(1):203-17. doi: 10.1016/j.ccm.2013.09.007. Epub 2013 Dec 12.

[Roflumilast in combination with long-acting bronchodilators in the management of patients with severe and very severe COPD. A cost-effectiveness analysis for Germany].

Dtsch Med Wochenschr. 2013 Jan;138(4):119-25. doi: 10.1055/s-0032-1327416. Epub 2013 Jan 15.

Roflumilast for asthma: Weighing the evidence.

Pulm Pharmacol Ther. 2015 Dec;35 Suppl:S1-3. doi: 10.1016/j.pupt.2015.08.001. Epub 2015 Aug 13.

Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients.

Int J Chron Obstruct Pulmon Dis. 2015 Jun 15;10:1123-8. doi: 10.2147/COPD.S83205. eCollection 2015.

引用本文的文献

Chronic Obstructive Pulmonary Disease (COPD): Developments in Pharmacological Treatments.

Drugs. 2025 May 20. doi: 10.1007/s40265-025-02188-8.

Differential response to roflumilast in patients with chronic obstructive pulmonary disease: real-world evidence.

J Thorac Dis. 2024 Feb 29;16(2):1338-1349. doi: 10.21037/jtd-23-1129. Epub 2024 Feb 27.

The effects of benralizumab on airway geometry and dynamics in severe eosinophilic asthma: a single-arm study design exploring a functional respiratory imaging approach.

Respir Res. 2023 May 3;24(1):121. doi: 10.1186/s12931-023-02415-4.

Effects of Roflumilast on Patients with Chronic Obstructive Pulmonary Disease Treated with Inhaled Corticosteroid/Long-Acting 2 Agonist: A Meta-analysis.

Comput Math Methods Med. 2022 Jul 23;2022:8101099. doi: 10.1155/2022/8101099. eCollection 2022.

Phosphodiesterase-4 Inhibitors for Non-COPD Respiratory Diseases.

Front Pharmacol. 2021 Aug 5;12:518345. doi: 10.3389/fphar.2021.518345. eCollection 2021.

Innovating on Inhaled Bioequivalence: A Critical Analysis of the Current Limitations, Potential Solutions and Stakeholders of the Process.

Pharmaceutics. 2021 Jul 9;13(7):1051. doi: 10.3390/pharmaceutics13071051.

A Functional Respiratory Imaging Approach to the Effect of an Oscillating Positive Expiratory Pressure Device in Chronic Obstructive Pulmonary Disease.

Int J Chron Obstruct Pulmon Dis. 2020 Jun 4;15:1261-1268. doi: 10.2147/COPD.S242191. eCollection 2020.

Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease.

Cochrane Database Syst Rev. 2020 May 1;5(5):CD002309. doi: 10.1002/14651858.CD002309.pub6.

Interventions for promoting physical activity in people with chronic obstructive pulmonary disease (COPD).

Cochrane Database Syst Rev. 2020 Apr 16;4(4):CD012626. doi: 10.1002/14651858.CD012626.pub2.

Effects of Roflumilast on Rehospitalization and Mortality in Patients.

Chronic Obstr Pulm Dis. 2018 Dec 20;6(1):74-85. doi: 10.15326/jcopdf.6.1.2018.0139.

The effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

The effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients.

作者信息

机构信息

出版信息

相似文献

引用本文的文献